|
|
Volumn 369, Issue 20, 2013, Pages 1877-1880
|
|
Expediting drug development - The FDA's new "breakthrough therapy" designation
a a a a a |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
3,4 DIAMINOPYRIDINE;
ABT 267;
ABT 333;
ABT 450;
ALECTINIB;
ANTINEOPLASTIC AGENT;
ANTIVIRUS AGENT;
ASFOTASE ALFA;
ASUNAPREVIR;
BIMAGRUMAB;
BMS 791325;
DACLATASVIR;
DERMATOLOGICAL AGENT;
DRISAPERSEN;
ENTINOSTAT;
IBRUTINIB;
IVACAFTOR;
LAMBROLIZUMAB;
LDK 378;
LEDIPASVIR;
LUMACAFTOR;
OBINUTUZUMAB;
OFATUMUMAB;
PALBOCICLIB;
SD 101;
SEBELIPASE ALFA;
SERELAXIN;
SOFOSBUVIR;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VOLASERTIB;
ACUTE GRANULOCYTIC LEUKEMIA;
ACUTE HEART FAILURE;
ADVANCED CANCER;
BREAST CANCER;
CHRONIC LYMPHATIC LEUKEMIA;
CYSTIC FIBROSIS;
DIAGNOSTIC TEST;
DRUG APPROVAL;
DRUG DEVELOPMENT;
DRUG EFFICACY;
DRUG INDICATION;
DRUG LEGISLATION;
DRUG RESEARCH;
DRUG SAFETY;
DUCHENNE MUSCULAR DYSTROPHY;
EATON LAMBERT SYNDROME;
ENZYME DEFICIENCY;
EPIDERMOLYSIS BULLOSA;
FOOD AND DRUG ADMINISTRATION;
HEPATITIS C;
HUMAN;
HYPOPHOSPHATASIA;
INCLUSION BODY MYOSITIS;
LUNG NON SMALL CELL CANCER;
LYMPHOCYTOMA;
LYSOSOMAL ACID LIPASE DEFICIENCY;
MACROGLOBULINEMIA;
MANTLE CELL LYMPHOMA;
MELANOMA;
NONHUMAN;
PERTHES DISEASE;
PHARMACEUTICAL CARE;
PREDICTION;
PRIORITY JOURNAL;
SHORT SURVEY;
|
|
EID: 84887412695
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMp1311439 Document Type: Article |
|
Times cited : (121)
|
|
References (1)
|
